MKI67

Overview

MKI67 encodes Ki-67, a widely used nuclear marker of cellular proliferation. In biomedical research and pathology, Ki-67 is commonly assessed by immunohistochemistry to estimate the proportion of cells actively cycling, making it a practical indicator of tissue growth, regeneration, and hyperproliferative states. Because its expression is associated with proliferating cells rather than quiescent cells, MKI67 is frequently used as a readout of biological activity in normal development, injury, and disease.

Functionally, Ki-67 is most often interpreted as a proliferation-associated protein rather than a direct therapeutic target. In experimental settings, changes in Ki-67 staining can help characterize whether a treatment preserves, restores, or suppresses tissue cell turnover. It is often evaluated alongside markers of apoptosis and stress responses, such as BCL2 apoptosis regulator (Bcl-2) family proteins or proinflammatory cytokine-related pathways, to provide a broader picture of tissue injury and recovery.

Recent Publications Summary

Recent publications have continued to use MKI67/Ki-67 primarily as a proliferation-associated biomarker and predictive target across multiple tumor types. In hepatocellular carcinoma, one dual-center study explored whether T2-weighted MRI habitat-derived parameters could be linked to Ki-67 expression and tumor aggressiveness, while another computational multi-omics analysis of bisphenol A-related hepatocarcinogenesis identified MKI67 among six hub genes upregulated in HCC and reported high internal cross-validated diagnostic accuracy, though the authors noted that external validation is still needed 42359754Jun42118483May. In gliomas, a multimodal ConvNeXt-Tiny deep learning model was developed to simultaneously predict IDH mutation status and Ki-67 expression level, underscoring the continued use of Ki-67 in imaging-based tumor characterization 42361071Jun.

Several studies focused on Ki-67 as a clinically relevant marker for treatment stratification and prognosis in breast cancer and lymphoma. In HER2-positive breast cancer, a bi-centric retrospective cohort study evaluated whether Ki-67 scores could predict pathological complete response and invasive disease-free survival after first-line therapy 42068346May. In hormone receptor-positive/HER2-negative early breast cancer, the WSG ADAPT-HR+/HER2- and ADAPTcycle trials examined clinical and molecular predictors of endocrine response after short preoperative endocrine therapy, with low Ki-67 after treatment highlighted as a favorable prognostic indicator 41999978Apr. In diffuse large B-cell lymphoma, a prospective observational study compared dose-adjusted EPOCH-R with R-CHOP specifically in patients with high Ki-67 expression, reflecting ongoing interest in Ki-67 for therapeutic decision-making 42172280May.

Beyond its role as a biomarker, Ki-67 was also investigated as a functional contributor to cancer progression. In breast cancer mouse models, CRISPR screening and single-cell transcriptomic profiling of circulating tumor cells identified Ki-67 as an essential regulator of circulating tumor cell intravasation; its knockout reduced metastasis, and the mechanism was linked to reduced expression of genes involved in cell-cell adhesion, including CD47 and KLF4, rather than to reduced proliferation 42139058May. In pancreatic ductal adenocarcinoma, intrapancreatic fat deposition was associated with increased MKI67 expression alongside FABP5 upregulation and activation of JAK/STAT, PI3K/AKT/mTOR, and Ras/Raf/MEK/ERK signaling pathways, with the model showing accelerated tumor growth and metastasis 42251134Jun.

Ki-67 also appeared in non-oncologic and pathology-focused studies as part of broader histopathologic assessment. In an adolescent rat model of chronic stress-induced testicular damage, Ki67 immunohistochemistry was used alongside Bax, Bcl-2, and SIRT6 to evaluate testicular injury and the protective effects of Ashwagandha versus sertraline 42315798Jun. A case report on hepatic neuroendocrine tumors listed Ki-67 among key biomarkers used in diagnosis and treatment planning, reinforcing its routine role in tumor grading and multimodal management 42049452Apr.

What Changes, What Holds

1. Ki-67 remains mainly a proliferation readout, but imaging and multi-omics are extending how it is operationalized in tumors
REINFORCES These studies keep MKI67 in its established role as a proliferation-associated biomarker and prognostic correlate, now tied to radiologic habitat features and computational gene signatures in hepatocellular carcinoma and to multimodal prediction in glioma 42359754Jun42118483May42361071Jun. They do not displace the baseline account; instead, they broaden the ways Ki-67 is being inferred and used for tumor characterization, while external validation and clinical utility remain unsettled.

2. Ki-67 is being used more explicitly for treatment selection and response prediction in aggressive hematologic and breast Cancers
REINFORCES The new work sharpens the baseline’s point that Ki-67 is a practical indicator of biological activity by showing continued use in stratifying therapy response and prognosis, especially in breast cancer and diffuse large B-cell lymphoma 42068346May41999978Apr42172280May. Nothing here overturns the established view; rather, it supports Ki-67 as a clinically actionable marker whose value depends on context, timing, and how it is integrated with other predictors.

3. Ki-67 may also contribute to metastasis biology, not just mark proliferation
NEW DIRECTION These findings go beyond the Overview’s description of Ki-67 as a proliferation-associated readout and suggest a functional role in cancer progression, including intravasation and metastatic behavior 42139058May42251134Jun. That does not negate its biomarker use, but it does challenge the idea that Ki-67 is only a passive indicator. The preclinical evidence is still early; replication and mechanistic work are needed to decide whether this is a general property or tumor-specific.

4. Ki-67 continues to serve as a routine histopathologic marker in non-oncologic injury and tumor grading
REINFORCES The stress-injury model and hepatic neuroendocrine tumor report both fit the baseline account of Ki-67 as a standard marker of tissue activity, regeneration, and grading rather than a direct target 42315798Jun42049452Apr. These papers add examples of established practice, not a new role. They also show that Ki-67 remains useful alongside apoptosis and stress markers when interpreting tissue damage and recovery.

Overview update candidates: functional contribution to metastasis biology; continued use of Ki-67 for treatment stratification and prognosis in specific Cancers; imaging- and multi-omics-based prediction of Ki-67 expression in tumors.